Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 5/20 | 0.49 |
| ▸ | DRD3 | P35462 | 4/20 | 0.49 |
| ▸ | DRD4 | P21917 | 4/20 | 0.49 |
| ▸ | HTR2A | P28223 | 3/20 | 0.48 |
| ▸ | HTR1A | P08908 | 2/20 | 0.48 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.48 |
| ▸ | DRD1 | P21728 | 2/20 | 0.48 |
| ▸ | DRD5 | P21918 | 2/20 | 0.48 |
| ▸ | HTR7 | P34969 | 2/20 | 0.48 |
| ▸ | HRH1 | P35367 | 2/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7783722 | 0.91 | DRD2 (0.58) | DRD2DRD3DRD4HTR2AHTR2C | |
| SCHEMBL7792010 | 0.91 | DRD2 (0.58) | DRD2DRD3DRD4HTR2AHTR2C | |
| SCHEMBL7793845 | 0.80 | DRD2 (0.60) | DRD2DRD3DRD4HTR1A | |
| SCHEMBL7783724 | 0.80 | DRD2 (0.54) | DRD2DRD3DRD4HTR2AHTR2C | |
| SCHEMBL7788935 | 0.77 | DRD2 (0.50) | MAPTDRD2DRD3DRD4HTR2A | |
| SCHEMBL13648727 | 0.76 | DRD2 (0.62) | DRD2DRD3DRD4HTR2AHTR1A | |
| SCHEMBL9367644 | 0.76 | DRD3 (0.55) | DRD2DRD3DRD4HTR2AHTR1A | |
| SCHEMBL9367707 | 0.74 | DRD2 (0.51) | DRD2DRD3DRD4HTR2AHTR2C | |
| SCHEMBL7793853 | 0.74 | DRD2 (0.86) | DRD2DRD3DRD4 | |
| SCHEMBL7789486 | 0.74 | DRD2 (0.86) | DRD2DRD3DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0613465-B1 | 1,3-SUBSTITUTED CYCLOALKENES AND CYCLOALKANES AS CENTRAL NERVOUS SYSTEM AGENTS | WARNER LAMBERT CO (US) | 2001-10-04 | — | — | EP | claimed |
| JP-3193718-B2 | — | — | 2001-07-30 | — | — | JP | claimed |
| US-5409931-A | Dopaminergic, antipsychotic and antihypertensive agents | WARNER-LAMBERT COMPANY (US) | 1995-04-25 | — | — | US | claimed |
| EP-0613465-A1 | 1,3-SUBSTITUTED CYCLOALKENES AND CYCLOALKANES AS CENTRAL NERVOUS SYSTEM AGENTS | WARNER-LAMBERT COMPANY (US) | 1994-09-07 | — | — | EP | claimed |
| EP-0545095-A1 | 1,3-Substituted cycloalkenes and cycloalkanes as central nervous system agents | WARNER-LAMBERT COMPANY (US) | 1993-06-09 | — | — | EP | claimed |
| WO-1993010092-A1 | 1,3-SUBSTITUTED CYCLOALKENES AND CYCLOALKANES AS CENTRAL NERVOUS SYSTEM AGENTS | WARNER-LAMBERT COMPANY (US) | 1993-05-27 | — | — | WO | claimed |
| EP-0613465-B1 | 1,3-SUBSTITUTED CYCLOALKENES AND CYCLOALKANES AS CENTRAL NERVOUS SYSTEM AGENTS | WARNER LAMBERT CO (US) | 2001-10-04 | — | — | EP | disclosed |
| US-5409931-A | Dopaminergic, antipsychotic and antihypertensive agents | WARNER-LAMBERT COMPANY (US) | 1995-04-25 | — | — | US | disclosed |
| EP-0613465-A1 | 1,3-SUBSTITUTED CYCLOALKENES AND CYCLOALKANES AS CENTRAL NERVOUS SYSTEM AGENTS | WARNER-LAMBERT COMPANY (US) | 1994-09-07 | — | — | EP | disclosed |
| US-5314896-A | Dopaminergic agents, antipsychotic and hypotensive agents | WARNER-LAMBERT COMPANY (US) | 1994-05-24 | — | — | US | disclosed |
| EP-0545095-A1 | 1,3-Substituted cycloalkenes and cycloalkanes as central nervous system agents | WARNER-LAMBERT COMPANY (US) | 1993-06-09 | — | — | EP | disclosed |
| WO-1993010092-A1 | 1,3-SUBSTITUTED CYCLOALKENES AND CYCLOALKANES AS CENTRAL NERVOUS SYSTEM AGENTS | WARNER-LAMBERT COMPANY (US) | 1993-05-27 | — | — | WO | disclosed |